Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis
Long-term use of mepolizumab to treat EGPA was well tolerated and resulted in sustained reductions in OCS use.
Authors
- Paneez Khoury (ORCID: https://orcid.org/0000-0003-1800-0079)
- Rejina Verghis (ORCID: https://orcid.org/0000-0002-8322-213X)
- Peter F. Weller (ORCID: https://orcid.org/0000-0001-9580-560X)
- Richard Price (ORCID: https://orcid.org/0000-0001-8551-0349)
- Michael E. Wechsler (ORCID: https://orcid.org/0000-0003-3505-2946)
- G. Wolff (ORCID: https://orcid.org/0000-0002-4458-0700)
- Jared Silver (ORCID: https://orcid.org/0000-0003-4392-0950)
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
Institutions
- North Carolina Central University (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Jewish Health (US)
- North Hertfordshire College (GB)
- GlaxoSmithKline (United States) (US)
- NSK (United Kingdom) (GB)
- National Institute of Allergy and Infectious Diseases (US)
- MRC Biostatistics Unit (GB)
- University of Pennsylvania (US)
- University of Colorado Denver (US)
- Philadelphia University (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1002/art.43146
- Citations
- 11
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 18.35
Funders
- GlaxoSmithKline
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research